Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human, Mouse, Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||A 17 amino acid synthetic peptide near the carboxy terminus of human EPM2A|
|Purification||Antigen affinity chromatography|
|Contains||0.02% sodium azide|
|Storage Conditions||Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C|
|Tested Applications||Dilution *|
|Immunocytochemistry (ICC)||25 ug/ml|
|Immunofluorescence (IF)||25 ug/ml|
|Western Blot (WB)||1 - 2 ug/mL|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
A suggested positive control is SW480 cell lysate.
PA5-34436 can be used with blocking peptide PEP-1478.
The Epilepsy, progressive myoclonus type 2A protein (EPM2A) is a dual-specificity phosphatase that associates with polyribosomes. Mutations in this gene have been associated with myoclonic epilepsy of Lafora. EPM2A interacts with a number of proteins known to be involved in glycogen metabolism and has been shown to have robust phosphatase activity against a phosphorylated complex carbohydrate, suggesting that EPM2A may be involved in the regulation of glycogen metabolism.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Epilepsy progressive myoclonus type 2A; epilepsy, progressive myoclonic epilepsy, type 2 gene alpha; epilepsy, progressive myoclonus type 2, Lafora disease (laforin); EPM2; EPM2A; glucan phosphatase; lafora PTPase; laforin; LAFPTPase; MELF
EPM2; EPM2A; MELF; Tg(TcraK,TcrbK)TG-BFlv; TG-B